#USA #New York #Levi & Korsinsky #Securities Fraud #Geron Corporation

Class Action Lawsuit Against Geron Corporation: Understanding the Stakes

On April 8, 2025, Levi & Korsinsky, LLP announced the initiation of a class action lawsuit against Geron Corporation (NASDAQ: GERN). This legal action aims to represent investors who may have suffered losses due to alleged securities fraud occurring between February 28, 2024, and February 25, 2025.

The Allegations

The lawsuit implicates Geron Corporation in providing misleading information regarding the anticipated success and commercial viability of their drug, Rytelo (imetelstat). Investors were led to believe in the drug’s potential and the company’s ability to tap into a significant unmet medical need, particularly among first-line ESA-ineligible patients. Key statements by the company's officials minimized risks associated with Rytelo’s required weekly monitoring and downplayed the competitive landscape.

However, upon the release of Geron’s fourth-quarter financial results for fiscal 2024 on February 26, 2025, it became evident that the company’s growth expectations for Rytelo had not materialized. The firm disclosed that its sales were stunted due to seasonality, increasing competition, and general unawareness of the drug among potential patients. This announcement led to a sharp decline in Geron’s stock price, plummeting by approximately 32.07% from $2.37 to $1.61 in just one day.

Who Can Participate?

If you have experienced a financial loss as a Geron investor during the specified period, you are eligible to potentially join this class action lawsuit. Interested parties must act quickly, as the deadline to request appointment as lead plaintiff is May 12, 2025. Notably, there is no requirement for lead plaintiff status to be part of any recovery.

No Financial Risk Involved

Participating in this class action does not impose any costs or obligations on the investors. If found successful, class members could receive compensation without fronting any out-of-pocket expenses related to the lawsuit. Levi & Korsinsky emphasizes their commitment to representing shareholders, having built a reputation over the last two decades for securing financial redress in complex securities litigation cases.

Why Choose Levi & Korsinsky?

With a history of successfully winning significant settlements and litigating against high-stake corporations, Levi & Korsinsky has ranked among the top securities litigation firms in the United States over multiple years. They boast a dedicated team of over 70 professionals ready to assist clients through every facet of the litigation process.

Contact Information

Investors interested in joining this case or requiring more information can contact Joseph E. Levi at email protected] or call (212) 363-7500 for direct assistance. For those wanting to begin the process, further details can be found at their [website.

Conclusion

The unfolding situation around Geron Corporation highlights the significant risks often present in the biotech sector. With changing circumstances affecting stock value and investor sentiment, it’s crucial for stakeholders to remain attuned to developments and consider their legal options. The class action lawsuit represents a potential avenue for recourse for those adversely affected by Geron’s decisions, ensuring that investor rights are upheld in the face of corporate misrepresentation.